Postpartum Acne Treatment While Nursing

Pregnancy

ACOG lists topical benzoyl peroxide, azelaic acid, salicylic acid and glycolic acid among over-the-counter options, and says to contact an ob-gyn about ingredients not on that list. It advises against topical retinoids, hormone-blocking acne medicines and isotretinoin during pregnancy. ACOG says oral tetracyclines can discolor fetal teeth when taken after the fourth month and affect bone growth while taken. NICE's 2026 acne guideline also says topical retinoids and oral tetracyclines are contraindicated during pregnancy and when planning pregnancy. Oral isotretinoin must remain distinct from topical retinoids: the current DailyMed capsule label carries a boxed warning, contraindicates use in pregnancy, and says the capsules are available only through the iPLEDGE REMS. FDA's 2026 update says the REMS changes scheduled for August 8 were delayed until November 15, and prescribers must continue medical-setting pregnancy testing before treatment until changes are implemented. The MHRA's January 2026 update removed the second-prescriber requirement for patients under 18, but retained the Pregnancy Prevention Programme for people who may become pregnant. EMA's 2023 PRAC minutes said the benefit-risk balance for oral isotretinoin remained unchanged and called for further study of barriers to Pregnancy Prevention Programme adherence. For topical retinoids, a 2026 Nordic cohort of 3,869,586 infants found no increased risk of major congenital malformations after first-trimester exposure, but the cohort authors said topical retinoids should still be avoided in pregnancy given study limits. A 2026 meta-analysis of eight studies and 3,632,118 pregnancies found no significant increase in major malformations or spontaneous abortion; its authors noted that results were driven mainly by one large registry study. The new data add information but do not replace ACOG and NICE's current precaution. For spironolactone, ACOG advises against hormone-blocking acne drugs, and the current label and an animal study describe altered male fetal sex differentiation in rats. These animal findings are not human pregnancy outcomes.

Breastfeeding

LactMed describes topical benzoyl peroxide, azelaic acid and adapalene as low risk based on limited absorption or low blood levels, but says they have not been studied during breastfeeding and reports no published infant levels or outcome information. LactMed advises preventing infant contact with treated skin; its azelaic acid and adapalene entries say not to apply the medicine to the breast or nipple. A human absorption study of topical azelaic acid in six male volunteers estimated 3.6% absorption, while LactMed estimates 4%; this was not a breastfeeding study. A topical clindamycin pharmacokinetic study found that exposure varied by formulation and measured no clindamycin in most acne-patient samples; it did not measure milk or infant outcomes. LactMed reports no published breastfeeding-use data for oral isotretinoin. The current DailyMed label says breastfeeding is not recommended during treatment or for at least 8 days after the last dose. This label restriction is not evidence that an infant harm was measured. For spironolactone, one human milk study measured canrenone, a metabolite, in one 17-day-postpartum woman taking 100 mg daily; its authors estimated the infant might receive about 0.2% of the maternal daily dose. The abstract does not report infant outcomes. Combined hormonal contraceptive findings vary by postpartum timing, estrogen dose and route. LactMed's January 2026 entry summarizes U.S. timing guidance and the more restrictive WHO advice. In a WHO three-centre study, combined oral contraceptive users had a 41.9% milk-volume decline after 18 weeks, compared with 12.0% for progestin-only pills and 6.1% in non-hormonal controls; infant growth did not differ significantly. A 2025 report described two mothers with reduced milk production and infant growth during combined-pill use, with recovery after stopping. A 2026 questionnaire study of 172 breastfeeding women reported a 20% reduction in self-reported expressed milk volume with a vaginal ring, but not with low-dose oral combined pills. It was a short, nonrandomized self-report study, so it does not settle the wider question.

What was tested

The opened evidence includes a Nordic registry cohort and a 2026 topical-retinoid meta-analysis for pregnancy outcomes; a rat study of spironolactone; topical azelaic acid absorption in six healthy male volunteers; topical clindamycin absorption in healthy volunteers and acne patients; one spironolactone metabolite milk study; and contraceptive studies measuring milk volume and infant growth. The 2026 contraceptive questionnaire study followed 172 women across two time points about 7 to 10 days apart. LactMed reports no infant outcome information for benzoyl peroxide, azelaic acid or adapalene, and no milk levels or infant outcomes for isotretinoin. The topical absorption studies do not establish infant outcomes through milk.